Given your interest in Biotech you might enjoy my recent biotech piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme biocatalysis platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential
hey mate!
Given your interest in Biotech you might enjoy my recent biotech piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme biocatalysis platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential
https://www.slack-capital.com/p/exozymes-research-report
Hi Pablo, I'm wondering if you'd be interested to write A.I. Supremacy Newsletter a guest post.
The topic I'm looking for is:
"How Generative A.I. will Help Decode An Age of Synthetic Biology"
For more info read here: https://aisupremacy.substack.com/p/guest-posts-on-ai-supreamcy